DEST

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase III clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in Phase I clinical trial for the treatment of skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product, which is in preclinical stage for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Biofilm that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections.